T he frequency of restenosis after coronary or peripheral angioplasty ranges from 25% to 70%1-6 and averages 20% after carotid endarterectomy.7-9 To date, thermal,10-12 pharmacological,13'14 and mechanical15,16 approaches to the prevention of early occlusion and restenosis have not been successful. In 1969, Dotter17 reported successful
In this investigation, we measured the thrombi formed on two different types of stainless-steel mesh endoprostheses placed inside 3-mm expanded polytetrafluorethylene (ePTFE) grafts by incorporating the stent-containing segments into chronic exteriorized arteriovenous silicone rubber shunts in baboons. The extent of acute thrombus formation was measured in real time by scintillation camera imaging of autologous "'In platelet deposition. Because the synthetic antithrombin D-FPRCH2C1 has been shown to prevent platelet-dependent high-shear thrombus formation,30 we have also determined the capacity of D-FPRCH2Cl to inhibit stent thrombosis.
The baboon was selected as the experimental animal because it closely resembles humans with respect to its hemostatic mechanisms29,31-33 and its responses to antithrombotic agents in high-flow arterial systems.30,3435 ePTFE grafts were used for stent placement because these grafts are clinically relevant and have less thrombogenicity than other commonly used clinical graft materials.36
Methods

Animals
Fifteen normal male baboons (Papio anubis) were used in these studies. The animals weighed 8-12 kg and had been dewormed and observed to be diseasefree for at least 6 weeks before use. All procedures were approved by the institutional animal care and use committee and were in accordance with federal guidelines.37 Chronic arteriovenous shunts were surgically implanted between the femoral artery and vein using the method described previously. 38 pling procedure because reproducible and uniform platelet deposition required that there be no flow disturbance at the graft junction. The 3-mm graftsilicone rubber tubing apparatus was then connected to additional lengths of 3-mm silicone rubber tubings comprising the arteriovenous shunt system with 2-cm-long tapered Teflon connectors (Small Parts).
Stents
We investigated two types of stents, both measuring 3 mm i.d. and 15 mm in length after placement. The first device studied was a balloon-expandable (BE) stent made from tempered stainless steel and was a gift from Johnson & Johnson, New Brunswick, N.J. The endoprosthesis consisted of continuous tubular wire mesh that measured 1.67 mm in collapsed diameter ( Figure 2 ). Wire thickness was 150 ,um. The BE stents were compressed to fit snugly around collapsed coaxial angioplasty balloons. They were expanded in a controlled fashion to reach the diameter imposed by inflating the coaxial balloon to expand the steel fibers to the limits of the graft. Placement directly within the center of the ePTFE grafts was determined by direct vision. The six double rows of staggered slots assumed a diamond shape after expansion. The mesh configuration of the stent dictated the degree of shortening that occurred when the stent reached its ultimate diameter within the lumen. This design determined the proportion of open space to metal surface and the ratio of unexpanded to expanded diameter (which limits delivery catheter size). The open area of the stent ranged from 69% in the collapsed state to a maximum of 88% when fully expanded.
The second type of stent evaluated was a selfexpandable (SE), spring-coil device provided as a gift from Medinvent SA, Lausanne, Switzerland. It was fashioned as a cylinder woven from surgical-grade stainless-steel monofilaments (100 -,m diameter). Each monofilament was free to pivot at lattice crossing points and had sufficient flexibility to become elastically extended longitudinally with a consequent decrease in diameter. It specially designed catheter delivery system ( Figure  2 ). When the constraining membrane was progressively removed, the stent self-expanded. The length after expansion was 15 mm.
Laboratory Procedures
Autologous baboon blood platelets were labeled with 800-1,000 gCi`1In oxine as previously described35,38 and were reinjected at least 2 hours before grafts were placed and imaged. Labeling efficiencies averaged 90%. Platelet counts were performed before each study on whole blood collected in Na2-EDTA (2 mg/ml) with a whole blood analyzer (model 810, J.T. Baker Instruments, Piscataway, N.J.). In selected animals, repeated platelet counts were performed during and after the study to observe potential depletion. Template bleeding times were also performed by the technique described previously. 31 Activity levels of D-FPRCH2Cl were measured as antithrombin activity in plasma prepared from blood collected in acid-citrate dextrose (ACD; National Institutes of Health formula A) on samples obtained before and at the end of infusion. Plasma antithrombin activity levels were assayed immediately or plasma was flash-frozen at -70°C for subsequent assay, using a standard curve for D-FPRCH2C1 in the range of 0-150 tg/ml prepared in autologous pretreatment plasma. The unknown plasma samples were diluted in control autologous plasma to obtain a thrombin time that could be read on a standard curve. Thrombin times were also performed on samples obtained 30 minutes after stopping D-FPRCH2C1 infusion. 30 To assess heparin activity, activated partial thromboplastin times were measured before, 30 minutes after, and 60 minutes after injection. In an additional five animals, heparin (100 units/ kg) was given as a bolus 10 minutes before insertion of stented grafts. This regimen was used to simulate the clinical administration of heparin for short-term coverage associated with the use of cardiovascular devices, in which anticoagulation is produced for several hours by the injection of a large initial bolus of heparin. Porcine heparin (1,000 units/ml) was obtained from Elkins-Sinn, Inc., Cherry Hill, N.J.
Platelet Imaging
Dynamic images of the grafts and accompanying silicone rubber tubing were taken with a Searle PHO/ Gamma V scintillation camera (Siemens Medical Systems, Iselin, N.J.) with acquisition at 5-minute intervals for 60 minutes. Images (128 x 128 byte mode) were analyzed directly with a Medical Data Systems A3 computer (Medtronic, Ann Arbor, Mich.) without image smoothing or other manipulations. The 172-keV energy peak of 1`1In was acquired with a highsensitivity collimator and a 15% energy window. Silicone rubber tubing and graft were fixed in a groove precisely machined into Plexiglas to maintain a linear geometry and ensure a standard 1-cm distance from the surface of the collimator. Care was taken to position the camera directly over the midportion of the graft in which the stent was located. Images of the regions of interest 1.7x2.2 cm in area (lOx 13 pixels, as determined by direct calibration of point sources) of the stented graft segment and of the silicone rubber tubing proximal to the stented region were acquired. Subtracting the blood background counts per minute from the stent region emissions for each image corrected for circulating (nondeposited) radioactivity, yielding deposited radioactivity only. After 60 minutes, 1 ml of whole blood was drawn, placed inside 3-mm-i.d. silicone rubber tubing, and imaged for 5 minutes as described above (region of interest, 100 x 13 pixels). The activity of this blood standard was also corrected for the small fraction of circulating nonplatelet (i.e., plasma) isotope to give plateletassociated "'1In radioactivity in counts per minute per milliliter of whole blood.38 Total platelet deposition, which included both labeled and unlabeled cells, was calculated by dividing stent-deposited counts per minute by circulating platelet counts per minute (blood standard) and multiplying by the circulating platelet count (platelets per milliliter of whole blood) as measured in the blood standard sample. 30, 38 Morphology At the conclusion of the study, grafts (control and stented) were gently irrigated with normal saline, removed, and inspected for gross thrombus. They were perfused with 2.5% gluteraldehyde in 0.1 M phosphate buffer. Grafts were then dehydrated in increasing concentrations of ethanol, critical-point dried with Freon, and sputter-coated with appronimately 35 nm of carbon for scanning electron microscopy using a Hitachi Model S520 scanning electron microscope.
Data Analysis
Data were analyzed using the CLINFO Plus computer program provided by the Division of Research Resources, the Heart, Lung, and Blood Institute, National Institutes of Health. Comparisons between groups were made using Student's t test (two-tailed) for paired and unpaired data. Variance about the mean is reported as ± 1 SEM.
Results
Blood flow rates in the arteriovenous shunt ranged from 100 to 165 ml/min (130±15 ml/min) at the beginning of the study and 80 to 125 ml/min (99±11 ml/min) at the end of the study. In no instance was there a significant difference in mean flow rates between study groups (p>0.3 by paired t test). Moreover, in previous work using the vascular graft model, platelet deposition was not significantly altered over the range of flow rates of 200 to 70 ml/min (p>0.4), that is, those values spanning the variations in shunt flow rate observed in this study (S.R. Hanson, unpublished observations). Circulating platelet counts averaged 280±51 x 103/,ul, and there was no significant between-group difference in platelet counts before and after studies were performed (p>0.5; paired t test).
Platelet deposition on control ePTFE grafts (n = 11) was detected and reached a plateau value by 60 minutes of 0.87+0.15x109 platelets/cm (Figure 3) . Images showed uniform distribution of radioactivity over the entire length of the graft. No control graft occluded.
In contrast, endovascular BE stents within ePTFE (n=6) produced substantially greater platelet deposition ( Figure 3 ). By 60 minutes 4.37±0.68x109 platelets/cm were accumulated (p=0.003 compared with controls; Figure 3 In animals (n=10) treated with continuous infusion of D-FPRCH2Cl (100 nmol/kg/min) begun Figure 4) ; platelet deposition on D-FPRCH2Cl-treated SE stents was 0.01±0.01x109 (p=0.01 compared with untreated SE stents; Figure 5 ). Stented grafts were free of any visible thrombus, and none occluded.
The thrombin times were prolonged to more than 300 seconds, the aPTTs were prolonged to 243+±48 expandable (BE) endovascular stents within expanded polytetrafluoroethylene (ePTFE) grafts. Control ePTFE grafts (n = 11) in the arteriovenous fistula produced modest deposition (e). BE stents within ePTFE grafts (n=6) substantially increased platelet deposition (o; p=0.003 compared with controls). Infusion of heparin had no effect on stent-induced thrombosis (a; n=5; p>0.5 compared with untreated selfexpandable [SE] stents). Infusion of D-FPRCH Cl significantly reduced platelet deposition on BE stents (o; p =0.0008 compared with untreated BE stents).
seconds, and the template bleeding times were more than 30 minutes during the infusion of this dose of D-FPRCH2C1. Thirty minutes after discontinuing the infusion of D-FPRCH2C1, the bleeding time had normalized (5.0± 1.6 minutes;p>0.5), the aPfls had returned to baseline (p>0.3), and the thrombin times averaged 20 seconds compared with the control times of 10 seconds. Plasma levels of D-FPRCH2CI were not detectable before infusion, 4.30±0.5 vg/ml at the end of infusion, 0.1±0.04 gg/ml at 30 minutes after stopping the infusion, and undetectable the next day.
There was no clinical evidence of spontaneous bleeding episodes in any of the animals studied. Scanning electron microscopy of the untreated ePTFE grafts showed detectable platelet deposition ( Figure  6A ), which became abundant on intraluminal stents in both untreated and heparin-treated animals ( Figure  6B ). Platelet deposition on stents in animals treated with D-FPRCH2C1 was abolished ( Figure 6C ). Discussion This study demonstrates that platelet deposition is substantial on two different endovascular stents placed within ePTFE grafts under high-flow conditions in nonhuman primates and that thrombus formation is abolished by infusion of the synthetic antithrombin D-FPRCH2Cl but resistant to comparably anticoagulating levels of heparin. Resistance of platelet-dependent thrombotic processes to heparin has been reported previously. The early durability of stented vessels appears to be related to the potential for thrombus formation and occlusion, and the late outcome is dependent on the completeness of endothelialization.25-27,56 Until endothelialization is realized, initial antithrombotic therapy with a synthetic antithrombin may be useful because of its potent and immediate inhibition of arterial thrombosis after stent deployment. The required duration of treatment and the safety of such agents remain to be defined.
